#Fractyl

[askvectorprime]

Dear Vector prime, sir, may i ask two questions. Why Rosanna(a cassette) doesn't shows up in shows? I remember, she was in Animated series, but was she anywhere else?

Dear Gig Worker,

Oh dear, did you have a ticket booked for one of her shows? I'm afraid she ended up having to withdraw from the remaining dates of her "Continuities" tour, after her show at the Fractyl Amphitheater. Sadly, towards the end of her set, her vocoder blew, leaving her unable to sing. The crowd knew what had happened right away, and they sung the rest of the song back to her, with the booming baritone of Grandus unmistakable amongst the chorus of the fans. It was a very emotional night for everyone. I'm surprised you didn't hear, it was all over the news. Still, the Choirs of Anduria carried on and performed even on the dates Rosanna couldn't show for, so if you did attend, I hope you had an enjoyable evening nonetheless. If you contact the venue, you may be able to get a refund on the face value of the ticket.

Rosanna hasn't performed in public since then, but rumor has it she's going to be making a big announcement very soon. The surprise release of a new single, "Your Weakness", has led many to believe that she'll be releasing her next album imminently—though as always there are plenty who suspect that the reveal will be of a more personal nature!

[impact-newswire]

Fractyl Health

[heyyoumewtwo]

Inspired by the cut TFA episode thatwould've depicted the alternate universe where Elita becomes a Prime, the Autobot twins Jetfire and Jetstorm are captured by the Predacon leader Arachnus Prime and are converted into the two technorganic recruits; Terrorsaur and Fractyl. Maintaining their ability to combine into one another, the twins can become the uncontrollable Magmagale!

[meetyoualltheway]

About Rosanna

Rosanna of Fractyl is a Cybertronian pop idol singer. She exists in the Kiss Players and TFA canons. She is also seen at a protest in the IDW 2005 comics with her purple sister, Flip Sides.

Flip Sides and Rosanna are cassetticons and they are the same model as Rewind and Eject, but with feminising modifications, such as a metal "skirt". Although all of Rosanna's toys have been sold with weapons, she doesn't seem to use them in canon. There is an implication in some canon materials that Rosanna (who is an Autobot) and Filp Sides (who is a Decepticon) may be the same person, but I don't play them that way.

I can play her from KP or TFA equally well. I know KP very well. I can also play the one in my Voice of Stanix fics. I do not mind playing KP verse as long as people aren't gross about it.

I don't have a lot of rules--they're all pretty obvious things, except one.

No god-modding or killing/maiming or NSFW happens to my characters without my explicit consent in direct messages.

Do not rush into relationships with my characters. It is OK to assume friendships that exist in canon but nothing further.

Don't assume that you know stuff about Rosanna that your character wouldn't canonically be in a position to know.

I do not care if male characters flirt with Rosanna, because dudes flirt with lesbians all the time. But as a player you should know that my Rosanna is a lesbian and your male characters have no chance of getting anywhere with her. She will not go out with them except as friends and she will never pop her panels for them. She is gay gay gay for girls girls girls.

No minors and especially no minors in my NSFW.

Rosanna canonically has exotic pets and in TFA she had a lot of them. I will joke about Carole Baskin coming after her because Carole Baskin is a joke, but I will block animal rights propaganda. My feelings about exotic pets are a) not exactly the same as Rosanna's b) not something I'm willing to fight about in an RP blog.

[fractyll123]

Fractyll offers a dynamic cultural lens on art, wellness, travel, and social movements, weaving a tapestry of stories that inspire and elevate. Through in-depth articles, profiles, and reviews, Fractyll dives into diverse topics that shape our world—celebrating creativity, wellness, and lifestyle innovation while connecting readers to impactful events and people. 

[insideoutvietnam]

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

Single administration of Rejuva reduced fat mass and improved glycemia in the well-validated diet-induced obesity (DIO) mouse model Rejuva also prevented weight and glycemic rebound after semaglutide withdrawal Data provide first demonstration that Rejuva treatment has potential to mimic natural release of GLP-1 from pancreas BURLINGTON, Mass., June 23, 2024 (GLOBE NEWSWIRE) — Fractyl Health,…

[hypeptide]

2023 global peptide event overview delivery

Part1 Financing/BD Event

December 2023

Kintide Pharmaceuticals completed US$8 million in seed round financing to advance a highly integrated computational design-automated synthetic peptide drug discovery platform

Roche acquires Carmot Therapeutics for over US$3 billion, entering the GLP-1 competition

Fractyl Health said in a regulatory filing that it plans to conduct an IPO in 2024. The company is committed to developing innovative treatments for type 2 diabetes and obesity, and the funds raised will be used to advance the development of its pipeline, including a gene therapy that expresses a GLP-1 receptor agonist in the pancreas.

Amide Technologies announced that it has begun commercializing its novel peptide manufacturing platform and has completed $16.5Mn in financing, including a $7.5Mn Series A+ round led by Engine Ventures with participation from Forcefield Venture Fund. It previously raised a $3.55Mn Series A round led by Engine Ventures and a $5.45Mn Seed round led by Biological Engineering Ventures.

Alkermes plc announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland, to Novo Nordisk. Under the terms of the agreement, upon completion of the transaction, Alkermes will be entitled to a one-time cash payment of $92.5Mn for the facility and associated assets, subject to customary adjustments in accordance with the agreement.

November 2023

Zhifei Biotech plans to acquire 100% equity of Chongqing Chenan Biopharmaceutical Co., Ltd. in cash to enter the GLP-1 field

Chengdu Taihe Weiye Biotechnology Co., Ltd. completed nearly 300 million yuan in Series A+ financing to accelerate the company’s Fmoc amino acid production capacity construction

Peptide Biotech completed nearly 200 million yuan in Series B+ financing to promote the development of GLP-1 products

lmagine Pharma completed US$32.5 million in Series A financing to develop new peptide IMG-1 and other projects

September 2023

PeptiDream enters into a new multi-target collaboration and licensing agreement with Genentech, a Roche company, to discover and develop novel macrocyclic peptide-radioisotope (peptide-RI) conjugates

Elicio Therapeutics receives $2.6 million foundation grant to fund research into two therapeutic cancer peptide vaccines

Shenzhen Tuosheng Biotechnology Co., Ltd. announced the completion of tens of millions of RMB Pre-A round of financing

August 2023

PeptiGrowth Inc (PeptiGrowth) and Orizuru Therapeutics, Inc (OZTx) have signed a joint development agreement to create a new synthetic peptide to replace recombinant growth factors used in the production of regenerative medicine products

HBC lmmunology completed US$900,000 in seed round financing to advance the research and development of peptide drugs

June 2023

Sino Biopharmaceuticals and Hongyun Huaning (Hangzhou) Biopharmaceutical Co., Ltd. have reached a cooperation agreement to jointly develop the dual-target innovative weight loss drug GMA106. GMA106 is a dual-target drug mainly suitable for the treatment of obesity, non-alcoholic fatty liver disease and diabetes

May 2023

Carmot Therapeutics announces raising $150 million in super Series E funding to advance its development of treatments for obesity and diabetes

lronwood successfully acquires next-generation GLP-2 through acquisition of VectivBio for $1 billion

Annual Highlights of Blockbuster Products

December 2023

Eli Lilly announced that its injectable Zepbound (Tirzepatide) is now available in U.S. pharmacies

Lisata Therapeutics announced that it has completed enrollment in the Phase IIb ASCEND study of its novel drug LSTA1 for the treatment of metastatic pancreatic ductal adenocarcinoma (“mPDAC”), achieving a key milestone.

Italian company Nerviano Medical Sciences (NMS) and Spanish pharmaceutical company Italfarmaco (ITF) jointly announced that ITF will use NMS’s proprietary linker-payload technology to develop a new PDC product candidate.

Apellis presented post-hoc data for its bicyclic peptide drug EMPAVELI® (pegcetacoplan) at the ASH Annual Meeting that strengthen the efficacy of EMPAVELI (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) for up to three years. years of long-term efficacy and safety.

November 2023

Eli Lilly announced that its GIP/GLP-1 receptor dual agonist Zepbound (Tirzepatide) has been approved by the U.S. FDA to reduce weight and maintain weight stability in obese or overweight adult patients.

Novo Nordisk released its results for Q3 and the first three quarters of 2023. Sales of semaglutide in the first three quarters have exceeded US$14.2 billion.

Eli Lilly and Company released its financial report for the third quarter of 2023. Sales of Tirzepatide in the first three quarters have reached US$2.957 billion.

October 2023

Novo Nordisk announced that the Phase III clinical study FLOW of semaglutide in patients with type 2 diabetes and chronic kidney disease with renal insufficiency was terminated early due to excellent efficacy.

August 2023

Eli Lilly’s Tirzepatide Injection Submits Registration Application in China for Long-term Weight Management Indication in Adults

July 2023

Eli Lilly announced the results of two phase 3 clinical trials on tilpotide. The results showed that the average weight loss effect was as high as 26.6%, making it the most powerful weight loss drug in history.

Peptide drugs approved for marketing

December 2023

Tonghua Dongbao Pharmaceutical’s marketing application for biosimilar GLP-1 analog liraglutide injection filed under registration classification 3.3 has been approved

Ascendis Pharma announced that the FDA has accepted the company’s resubmitted New Drug Application for palopegteriparatide (TransCon PTH) for the treatment of adult patients with hypoparathyroidism.

The National Medical Insurance Administration officially announced the adjustment list of the 2023 version of the National Medical Insurance Drug Catalog. The new round of medical insurance catalog includes four popular GLP-1 products. These include Renhui Biotech’s benaglutide injection, Lilly’s dulaglutide injection, Hanson Pharmaceuticals’ polyethylene glycol loxenatide injection, Novo Nordisk’s semaglutide injection, etc.

September 2023

BioLineRx announces FDA approval of Aphexda (motixafortide) combined with filgrastim (granulocyte colony-stimulating factor G-CSF) to mobilize hematopoietic stem cells into the peripheral blood as a stem cell mobilization (SCM) to promote autologous transplantation in patients with multiple myeloma at the time of transplantation

The marketing application for new indications of Lilly’s dulaglutide injection (trade name: Duida) was approved

July 2023

Renhui Biotech’s benaglutide has been approved for marketing as a new indication for weight loss. This is the first original new weight loss drug in China, and the injection frequency is three times a day.

East China Medicine’s Liraglutide Injection is approved for marketing for obesity or overweight indications

June 2023

Hansoh Pharmaceutical’s Class 1 new drug “Pemoxatide Injection” (trade name: Saint Relais) was approved for marketing. This medicine is suitable for adult non-dialysis patients who are not receiving erythropoiesis stimulating agents (ESA), and adult dialysis patients who are receiving short-acting erythropoietin (EPO).

May 2023

Blue Earth Diagnostics’ radiohybrid prostate-specific membrane antigen (PSMA)-targeted PET imaging agent Posluma (flotufolastat F 18) injection (formerly known as 18F-rhPSMA-7.3) was approved by the FDA for marketing

March 2023

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years and Older

Cidara Therapeutics’ New Drug Application (NDA) for Rezafungin for the treatment of candidemia and invasive candidiasis was approved by the FDA

January 2023

Radius Health’s TYMLOS (abapatide) received U.S. FDA approval for new indication (osteoporosis)

Website: https://www.ks-vpeptide.com/aboutus.html

[chapteratatime]

Check out my latest video

Predacon Fractyl

Beast Wars Source Book

#maccadom #transformers #predaconsvsmaximals #maccadoms #maximal #predacon #beastwarstransformers #beastwarssourcebook #riseofthebeasts #beastwars #IDW #idwtransformers#idwtransformerscomic #idwtransformers #Transformerscomics #idwcomics #idwbeastwars

#fractyl #pterodactyl

[labnotes19]

A One-Time Shot for Type 2 Diabetes? A Biotech Company Is On It

Fractyl Health is developing a gene therapy alternative to drugs like Ozempic and Wegovy to control blood sugar and body weight without repeated injections. from Science Latest https://ift.tt/0X3gG24 via IFTTT

[fractyll123]

Fractyll celebrates diverse cultural expressions with a focus on elevating and preserving artistic voices through engaging content. Covering features, reviews, profiles, and event coverage, Fractyll dives into the stories that shape music, art, fashion, and social movements, offering readers an immersive journey into creative worlds. Driven by a passion for authenticity, Fractyll curates insightful pieces that reflect the intricacies of contemporary culture, aiming to empower both creators and audiences alike. 

[tgping]

Turns out I can’t stream today, in preparation for #megaconorlando, but I’ve got a good scan of Fractyl, painting 33 of 36 for my S2 BW artbook. Pre0rder before I finish 36 of 36 by DMing me ;) - - - - - - - - - - - - #transformers #beastwars #transformersriseofthebeasts #botcon #fractyl #pteranodon #scifi #fantasy #watercolor #watercolorpainting #painting #watercolorart #igart #igartist #instaart #instaartist #mecha #energon (at DeLand, Florida) https://www.instagram.com/p/Cds4UJNORlM/?igshid=NGJjMDIxMWI=

[thepumpkintimekeeperec]

Yo, I’m pretty sad right now. Here are some beasties

I really like drawing beast wars characters, but damn they’re pretty hard to get good. Hope y’all enjoy.

[seaquestions]

hello welcome to the wreckers yes we are all gay why do you ask

[barricade643sg]

Dear, Vector Prime.

I once read Jesse Wittenrich tell a story about "Tri-Nox" and how he was turned into a ceratopsian dinosaur by Malgus Blackarachnia.

Primal Minor arrives in a strange jungle and discovers a group of semi-organic Decepticons led by Blackarachnia, who continues to experiment, creating "Fractyl," "Terrorsaur," "Inferno," "Antagony," and a self-centered tyrant reminiscent of her former boss, "Megatron."

To Minor's horror, among the Decepticons was his friend who had been renamed "Tri-Nox," given a prehistoric beast mode, and enslaved with control collars and brainwave bolts. The stubborn Autobot explorer, alone He must fight the Decepticons (Predacons) and, while waging guerrilla warfare, attempts repeatedly to defeat Blackarachnia, who control the Tri-Nox.

(Primal Minor and purple Megatron image source https://news.tfw2005.com/2017/02/26/transformers-animated-anthology-fan-artbook-japan-334748#images)

Dear Vector Prime, what other animals has Rhinox become in different realities?

Dear Rhino Researcher,

In a reality where the Axalon and Darksyde crashed only a few thousand years in the past, Rhinox adopted the form of a cold-adapted woolly rhinoceros. In another universe where the Maximals and Predacons arrived on Earth fifty million years in your future, he instead chose to became a heavy-set antelope descendant; on another variant Earth where the dinosaur-killing meteor never hit your world, he scanned a grassland-adapted ceratopsian dinosaur. It seems as though, no matter the universe, the ‘bot who usually goes by “Rhinox” has an affinity for a very specific form…

[autoacafiles]

[speedfreak01]

toxitron+dreadwind+darkwing+blot+fractyl+pteraxadon= NOXIOUS MAXIMUS

the ultimate goon-biner